Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
The role of incretin receptor agonists in the treatment of obesity
The role of incretin receptor agonists in the treatment of obesity
Fuente:
Wiley Open Access
Saved in:
Bibliographic Details
Main Authors:
Thomas Forst
,
Christophe De Block
,
Stefano Del Prato
,
Sara Armani
,
Juan Frias
,
Anne Lautenbach
,
Bernhard Ludvik
,
Marina Marinez
,
Chantal Mathieu
,
Timo D. Müller
,
Oliver Schnell
Format:
Artículo Open Access
Published:
Wiley
2024
Subjects:
Diabetes, Obesity and Metabolism
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Description
DOI:
10.1111/dom.15796
Similar Items
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
by: Nadine Beetz, et al.
Published: (2024)
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
by: Tommaso Bucci, et al.
Published: (2025)
What is the ‘real‐world’ experience with fixed‐ratio combination therapy (insulin + GLP ‐1 receptor agonist) in routine clinical practice? Take‐home messages for clinicians regarding key outcomes
by: Juan Pablo Frias
Published: (2025)
Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
by: Renata Spezani, et al.
Published: (2025)
Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
by: Huilin Tang, et al.
Published: (2025)